Natural history of granulosa cell tumors of the ovary
=====================================================

Granulosa cell tumors (GCTs) of the ovary are relatively uncommon neoplasms, representing approximately 5 to 10% of all ovarian malignancies \[[@B1],[@B2]\]; the others are germ cell tumors (teratomas and yolk sac tumors, 60 to 70%) and epithelial adenomas (10 to 20%) \[[@B3]\]. GCTs of the ovary belong to the group of ovarian sex-cord stromal tumors. Other tumors in this class are thecoma-fibromas, Sertoli cell tumors, sex cord tumors with annular tubules, and gynandroblastomas. The majority of patients with GCTs are adults, but 5% are pre- or peri-pubertal \[[@B4]\]. Consequently, two histological types of GCTs can be distinguished on a histopathological basis: juvenile and adult. GCTs exhibit several morphological, biochemical and hormonal features of normal proliferating pre-ovulatory granulosa cells, including both estrogen and inhibin biosynthesis \[[@B5]\]. This tumoral hyperestrogenism induces precocious puberty in children (premature breast development, vaginal bleeding) and advanced growth and bone maturation. The prognosis of juvenile GCTs is excellent overall: tumor recurrence and metastasis are rare and usually occur early \[[@B6]\]. On the other hand, adult GCTs are low-grade indolent malignant neoplasms that display a significant propensity for recurrence and metastasis, and they may cause menorrhagia or inter-menstrual bleeding. The cornerstone of treatment remains surgery. The disease in young patients is often confined to one ovary and thus, in order to preserve fertility, a unilateral salpingo-oophorectomysubunit andis is preferable.correlated In the case of post-menopausal women, a total abdominal hysterectomy and bilateral salpingo-oophorectomy should be performed \[[@B7]\].

Challenges in GCT management
============================

Nevertheless, management of patients with ovarian GCTs needs to be improved. First, the recurrent or metastatic tumor may manifest many years after removal of the primary neoplasm, with intervals of 10 or even 20 years being not uncommon, especially in the adult disease \[[@B8],[@B9]\]. Clinical follow-up of these patients is thus critical, but prognostic factors are lacking and assessment of the recurrence risk remains imprecise. For instance, in International Federation of Obstetricians and Gynecologists (FIGO) stage I disease (that is, intra-ovarian tumor with no extension, the most frequent stage at diagnosis according to FIGO), no association between outcome and the clinical signs or tumor histology (mitotic, nuclear atypia, ploidy, Ki67 expression) has been undisputedly demonstrated \[[@B10],[@B11]\]. Furthermore, in more advanced disease, aggressive debulking surgery and postoperative chemotherapy may be required \[[@B8]\]. Alternative treatment options and the use of molecular markers are thus necessary, especially for young women whose fertility should be preserved.

*FOXL2*and GCTs of the ovary
============================

*FOXL2*is a recent candidate gene in the pathophysiology of GCTs and could prove useful to evaluate their prognosis. Indeed, *FOXL2*is a winged helix/forkhead transcription factor gene involved in ovarian development and function \[[@B12],[@B13]\]. FOXL2 ovarian expression in mammals starts before the morphological differentiation of the gonad is recognizable, and persists until adulthood, mainly in granulosa cells \[[@B14],[@B15]\]. FOXL2 is thought to be a key factor in the early development and maintenance of the vertebrate ovary \[[@B12],[@B15]\]. Its expression in granulosa cells is suppressed, or at least lowered, in the majority of juvenile GCTs, particularly in those with the most aggressive pattern of progression \[[@B16]\]. Similar expression studies have yet to be performed in adult GCTs.

Interestingly, Shah *et al.*\[[@B17]\] recently studied four adult GCTs using whole-transcriptome paired-end RNA sequencing. After removing the previously described germline genetic variants and non-specific mutations present in non-GCTs, the authors identified the somatic missense point mutation c.402C→G (p.C134W) in all four specimens. Subsequently, they used direct sequencing, restriction fragment length polymorphism analyses (RFLPs), and a real-time PCR-based allelic discrimination assay to genotype *FOXL2*in a large collection of tumors. The p. C134W mutation was found in 97% of 89 additional adult GCTs studied, and was detected in only one case out of eight juvenile GCTs. The mutation was also found in 21% of thecomas, that is, 3 out of 14, in the study of Shah *et al*. Further studies are needed to determine the link between this mutation and GCTs, and whether this mutation alone is sufficient to induce tumor progression.

Other genetic factors implicated in ovarian GCTs
================================================

Genetic defects in other signaling pathways have been investigated in GCTs. Although Peutz-Jeghers syndrome is associated with an increased risk for GCTs, neither allele loss at the disease locus (19p13.3) nor mutations in the *LKB1*gene are associated with sporadic GCTs \[[@B18],[@B19]\]. Similarly, despite the association of epithelial ovarian cancer with the familial breast cancer genes *BRCA1*and *BRCA2*, sporadic mutations have not been reported for GCTs.

Other interesting candidate pathways are those involving the mitogen-activated protein kinases \[[@B20]\] and growth factors, because they are known to induce increased oncogene functioning or a loss-of-anti-oncogene function in several solid tumors. However, King *et al*. \[[@B21]\] failed to identify any prognostic value for the oncogenes *c-myc*, *p21-ras*, *c-erb B2*, and *p53*in a group of 40 GCTs. Similarly, the Wilms\' tumor suppressor gene (*WT1*) and *TP53*genes, which play a role in follicular development, have been tested \[[@B22]\]. *WT1*is expressed in GCT, but neither mutations nor loss of heterozygosity have been identified \[[@B23]\]. *TP53*mutations are frequent in numerous cancers, especially in epithelial tumors of the ovary, but there is neither hyperexpression \[[@B24]\] nor mutation \[[@B25]\] of this gene in GCT.

The role of the follicle-stimulating hormone (FSH) signaling pathway is also strongly suspected in GCTs for two reasons: firstly, normal granulosa cells are under the control of FSH and, secondly, the gene expression profile of GCTs is consistent with a constitutive activation of FSH signaling \[[@B26]\]. However, there is no evidence of activating mutations in the gene encoding the FSH receptor \[[@B27]-[@B29]\]. FSH signaling involves the coupling of heterotrimeric G proteins to activate intracellular second messenger systems, mainly the cAMP-dependent protein kinase (PKA).

Conflicting data have been reported regarding the presence of a constitutive activating mutation of the Gsα subunit in GCTs, the so-called *gsp*oncogene. It has rarely been described in adult GCTs \[[@B30],[@B31]\], but our group has identified it frequently in the juvenile type, where mutations in hot spot position 201 (p.R201C or p.R201H) were found in 30% of patients \[[@B32]\]. The precise role of this mutation in the transformation of ovarian cells into malignant cells remains unclear, but it has been demonstrated in other tissues that the rate of cell proliferation and invasiveness can be influenced by the constitutive activation of Gαs \[[@B33]\]. The oncological stages are indeed significantly different according to the *gsp*oncogene status. Patients with a cantly more advanced tumors, and almost 80% of *gsp*-positive patients present with an extra-ovarian extension (stage Ic) or have a recurrence \[[@B32]\].

Potential diagnostic and therapeutic applications
=================================================

The clinical applications of these findings may be promising in the near future, for several reasons. Firstly, identification of a recurrent mutation in *FOXL2*may be used as another diagnostic tool for adult GCTs, in addition to the classical pathological and immunohistochemical features. It may be particularly useful to explore granulosa tumor participation in heterogeneous ovarian non-germinal tumors with components of different origins. Also, the low frequency of the *FOXL2*mutation in juvenile GCTs compared with adult cases, as reported by Shah and collaborators \[[@B17]\], supports the distinction made between the juvenile type and the adult type based on clinical presentation, pathological features and natural progression \[[@B1]\]. Clearly, differentiating the two types of tumor is clinically relevant, since relapses of adult GCTs are more frequent and may occur later than juvenile GCTs. The mutational or expressional status of *FOXL2*could thus be of importance in adapting the length of postoperative follow-up. Another genetic abnormality that could be critical in the follow-up of these patients is the *gsp*oncogene status, especially for juvenile GCTs. A constitutively activated Gsα is indeed involved in the natural history of the tumor and is a prognostic factor of its extension. Finally, the finding of both extinction \[[@B16]\] and mutation \[[@B17]\] of *FOXL2*in GCTs highlights the role of this gene in the regulation of cell proliferation. These findings increase the body of evidence implicating the *FOX*family genes, whether as oncogenes or anti-oncogenes, in malignant processes such as rhabdomyosarcomas \[[@B34]\], secondary acute myeloblastic leukemia \[[@B35]\], and laryngeal, lung, breast \[[@B36]-[@B38]\] and pancreatic cancers \[[@B39]\]. *FOXL2*may act as a transcriptional regulator and a coordinator of SMAD3 downstream targets \[[@B40],[@B41]\] that, with SMAD2 and the TGF-β superfamily ligands, regulate granulosa cell proliferation \[[@B42]\]. These recently identified steps could be the targets of the next generation of therapies.
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